New Health Positioned for Launch of Oral GLP-1 Therapy
MedPal AI (LSE:MPAL) believes its private weight-management platform, New Health, is well placed to benefit from the UK launch of the first oral GLP-1 receptor agonist approved for weight loss following an earlier-than-expected authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA).
The treatment is currently available only through private prescriptions, creating an opportunity for providers capable of delivering accessible and scalable weight-management services. MedPal AI expects growing interest from patients seeking an alternative to injectable therapies as New Health expands its national rollout.
Technology Platform Designed to Support Growing Demand
The company’s offering combines AI-powered patient triage, clinician supervision and automated pharmacy fulfilment to streamline the treatment pathway from consultation to prescription delivery.
Through this integrated model, MedPal AI aims to provide a convenient route for patients seeking weight-loss therapies while leveraging its digital healthcare infrastructure to manage increasing demand efficiently.
Management believes the availability of an oral treatment option could broaden the appeal of GLP-1 therapies among individuals who may be reluctant to use injectable medications.
U.S. Adoption Highlights Market Potential
The board has pointed to the strong commercial performance of oral semaglutide in the United States as an indicator of potential demand in the UK market.
According to the company, more than three million prescriptions have been issued in the U.S. within just over five months of launch, with many users being first-time GLP-1 patients. MedPal AI believes this trend demonstrates how tablet-based therapies can expand the addressable market beyond traditional injectable treatment users.
Private Market Opportunity Remains Significant
With NHS access not currently available and a formal evaluation by the National Institute for Health and Care Excellence (NICE) still pending, the company sees a substantial opportunity within the private healthcare sector.
Management believes this environment could strengthen New Health’s competitive position and support continued growth across MedPal AI’s broader digital healthcare and pharmacy operations as demand for weight-management treatments continues to increase.
More About MedPal AI
MedPal AI Plc is a UK-based digital health and pharmacy technology company developing the MedPal Health OS, an AI-driven healthcare platform that integrates wellness tools, clinician-led services and prescription fulfilment.
Through its subsidiary, MedPal Limited, the group operates a 24-hour AI-enabled pharmacy distribution centre that provides nationwide NHS and private prescription services. The business combines artificial intelligence, robotic dispensing technology and rapid delivery capabilities to create a fully integrated digital healthcare ecosystem.
Leave a Reply